Home » Stocks » Nektar Therapeutics

Nektar Therapeutics (NKTR)

Stock Price: $22.08 USD -0.08 (-0.36%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $21.85 -0.23 (-1.04%) Aug 3, 4:45 PM

Stock Price Chart

Key Info

Market Cap 3.93B
Revenue (ttm) 136.97M
Net Income (ttm) -460.81M
Shares Out 177.99M
EPS (ttm) -2.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $22.08
Previous Close $22.16
Change ($) -0.08
Change (%) -0.36%
Day's Open -
Day's Range 21.96 - 22.45
Day's Volume 1,062,818
52-Week Range 13.63 - 31.39

More Stats

Market Cap 3.93B
Enterprise Value 3.00B
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 177.99M
Float 176.34M
EPS (basic) -2.62
EPS (diluted) -2.62
FCF / Share -1.96
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 27.36M
Short Ratio 26.52
Short % of Float 30.30%
Beta 1.99
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 28.69
PB Ratio 3.04
Revenue 136.97M
Operating Income -452.98M
Net Income -460.81M
Free Cash Flow -347.40M
Net Cash 933.83M
Net Cash / Share 5.25
Gross Margin 68.08%
Operating Margin -330.72%
Profit Margin -336.40%
FCF Margin -253.63%
ROA -12.57%
ROE -31.38%
ROIC -22.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (15)

Buy 8
Overweight 0
Hold 7
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$27.38*
(24.00% upside)
Low
18.0
Current: $22.08
High
43.0
Target: 27.38
*Average 12-month price target from 13 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1151,19330816523120114981.1971.48159
Revenue Growth-90.4%287.81%86%-28.32%14.99%34.77%83.42%13.59%-55.06%-
Gross Profit93.241,16927713519717211050.7649.59133
Operating Income-440688-59.64-113-29.37-16.49-120-141-124-28.26
Net Income-441681-96.69-154-81.18-53.92-162-172-134-37.94
Shares Outstanding17517015614013212711611511394.08
Earnings Per Share-2.523.78-0.62-1.10-0.61-0.42-1.40-1.50-1.19-0.40
Operating Cash Flow-329718-80.41-117-73.08-142-38.53-130-114-55.87
Capital Expenditures-26.29-11.61-9.68-6.39-11.20-9.98-4.09-10.58-9.72-31.46
Free Cash Flow-355707-90.09-123-84.28-152-42.62-140-123-87.33
Cash & Equivalents1,3251,335296389309263262302241316
Total Debt408247245243248134137137230232
Net Cash / Debt9171,08850.9314661.4212912516611.6383.96
Assets1,9772,150509569499442435498607521
Liabilities572433421481492405524451409431
Book Value1,4051,71887.8388.136.4336.33-89.9047.0219890.66
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Nektar Therapeutics
Country United States
Employees 723
CEO Howard W. Robin

Stock Information

Ticker Symbol NKTR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NKTR
IPO Date May 3, 1994

Description

Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.